Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Inclusion Criteria: * Female patients aged 18-70 years. * Diagnosed with locally advanced (T2-3, N2-3, M0 or T4a-c, any N, M0), inflammatory (T4d, any N, M0) or operable (T2-3, N0-1, M0), invasive breast cancer. * Primary tumor \> 2 cm in diameter. * HER2 positive breast cancer confirmed (Tumors must be IHC 3+ or FISH/CISH + for IHC 2+ tumors). * Baseline LVEF ≥ 55% measured by echocardiography. * Performance status ECOG ≤ 1 * Signed informed consent. Exclusion Criteria: * Metastatic disease (Stage IV) or bilateral breast cancer. * Previous anticancer therapy or radiotherapy for any malignancy. * Other malignancy, except for carcinoma in situ of the cervix or basal cell carcinoma. * Received any investigational treatment within 4 weeks of study start. * At least 4 weeks since major surgery. * Uncontrolled hypertension (systolic \> 150 and/or diastolic \> 100), unstable angina, CHF of any NYHA classification, serious cardiac arrhythmia requiring treatment, history of myocardial infarction within 6 months of enrollment. * Hematological, biochemical and organ dysfunction: 1. Inadequate bone marrow function: Absolute Neutrophil Count (ANC) \< 1500 cells/ µL, Platelet count \< 100,000 cells/ µL and Hb \< 9 g/dL). 2. Impaired liver function: serum \[total\] bilirubin \> 1.25 x ULN, AST/ALT \> 1. 5 x ULN with ALP \> 2.5 x ULN 3. Inadequate renal function: serum creatinine \> 1.5 x ULN. * Dyspnea at rest or other diseases which require continuous oxygen therapy. * Severe uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, metabolic, etc). * Current chronic daily treatment with corticosteroids (dose of ≥10 mg Oral prednisolone, or equivalent \[excluding inhaled steroids\]) * Subjects with known infection with HIV, HBV, and HCV. * Known hypersensitivity to any of the study drugs or excipients. * Pregnant and/or lactating women or subjects with reproductive potential not willing to use effective methods of contraception. * Subjects assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol (e.g.: physical, psychological and mental problems)